EGFR and lung adenocarcinoma: Possible candidates to undergo such mutations include a multitude of gene products described in studies of human lung tumors [53]–[62], some of these studies have implicated the EGFR/IL-6/Stat3 pathway in the pathogenesis of lung adenocarcinomas [43], [49], [50], [61]–[63].